ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $2.00 at Citigroup

ProQR Therapeutics (NASDAQ:PRQR) had its price objective increased by stock analysts at Citigroup from $1.80 to $2.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective would suggest a potential upside of 0.50% from the company’s previous close.

PRQR has been the subject of a number of other reports. StockNews.com cut ProQR Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of ProQR Therapeutics in a research report on Thursday, March 14th. Finally, Chardan Capital lifted their price objective on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a “buy” rating in a report on Thursday, March 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $3.60.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR opened at $1.99 on Thursday. ProQR Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $3.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.54 and a current ratio of 3.54. The company has a 50 day moving average price of $2.14 and a 200 day moving average price of $1.87. The stock has a market capitalization of $161.91 million, a P/E ratio of -5.10 and a beta of 0.21.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). ProQR Therapeutics had a negative return on equity of 56.71% and a negative net margin of 431.65%. The company had revenue of $3.54 million for the quarter, compared to analysts’ expectations of $27.88 million. Equities research analysts forecast that ProQR Therapeutics will post -0.37 EPS for the current year.

Institutional Investors Weigh In On ProQR Therapeutics

Several large investors have recently bought and sold shares of PRQR. Belvedere Trading LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at about $42,000. Tower Research Capital LLC TRC raised its holdings in ProQR Therapeutics by 164.8% in the first quarter. Tower Research Capital LLC TRC now owns 14,132 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 8,796 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in ProQR Therapeutics by 137.3% in the fourth quarter. BNP Paribas Financial Markets now owns 15,901 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 9,200 shares in the last quarter. Mariner LLC purchased a new position in ProQR Therapeutics in the fourth quarter worth approximately $68,000. Finally, Two Sigma Securities LLC acquired a new position in ProQR Therapeutics during the 1st quarter worth approximately $41,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).